Physician profile
Pravin K Sah
NPI 1609014851
$4,810.19
in general payments reported to CMS, 2019-2025
25 companies · $784 in 2025
The $784 reported for 2025 was more than what 84% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $687 · 2021: $710 · 2022: $487 · 2023: $515 · 2024: $654 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.33 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $863.00 | 2019-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $660.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $653.36 | 2019-2025 | Dupixent |
| Sobi, INC | $466.47 | 2019-2022 | |
| Covis Pharma Gmbh | $314.93 | 2019-2021 | |
| Philips North America LLC | $308.04 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Baxter Healthcare | $292.84 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $228.62 | 2019-2025 | Smartvest |
| Amgen INC. | $124.44 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $118.20 | 2019-2023 | Nucala |
| Sanofi-Aventis U.S. LLC | $102.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $99.63 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $98.90 | 2024-2025 | Daybue |
| Insmed, INC. | $76.95 | 2020-2021 | |
| Sanofi Pasteur INC. | $64.70 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $62.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.21 | 2022-2023 | Ofev |
| Teva Pharmaceuticals USA, INC. | $54.92 | 2021 | |
| Alcresta Therapeutics, INC. | $50.90 | 2023-2024 | Relizorb |
| Pfizer INC. | $23.70 | 2023 | |
| Monaghan Medical Corporation | $22.56 | 2025 | Aeroeclipse |
| Genentech USA, INC. | $18.87 | 2024 | Xolair |
| Pari Respiratory Equipment, INC. | $15.84 | 2019 | |
| Mylan Specialty L.P. | $15.57 | 2021 | |
| Merck Sharp & Dohme LLC | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pravin Sah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.